Towards population-specific pharmacogenomics in the era of next-generation sequencing

被引：7

作者：

Ji, Xiangjun ^{[1
,2
,3
]}

Ning, Baitang ^{[4
]}

Liu, Jinghua ^{[3
]}

Roberts, Ruth ^{[5
,6
]}

Lesko, Larry ^{[4
,7
]}

Tong, Weida ^{[4
]}

Liu, Zhichao ^{[4
]}

Shi, Tieliu ^{[1
,2
,4
,8
]}

机构：

[1] East China Normal Univ, Ctr Bioinformat & Computat Biol, Inst Biomed Sci, Shanghai 200241, Peoples R China

[2] East China Normal Univ, Sch Life Sci, Sch Stat, Shanghai 200241, Peoples R China

[3] Southern Med Univ, Sch Basic Med Sci, Guangdong Prov Key Lab Prote, Guangzhou, Peoples R China

[4] US FDA, Div Bioinformat & Biostat, Natl Ctr Toxicol Res, 3900 NCTR Rd, Jefferson, AR 72079 USA

[5] ApconiX, BioHub Alderley Pk, Alderley Edge SK10 4TG, England

[6] Univ Birmingham, Birmingham B15 2TT, W Midlands, England

[7] Univ Florida Lake Nona, Ctr Pharmacometr & Syst Pharmacol, Dept Pharmaceut, Orlando, FL USA

[8] Guangxi Med Univ, Natl Ctr Int Res Biol Targeting Diag & Therapy, Guangxi Key Lab Biol Targeting Diag & Therapy Res, Collaborat Innovat Ctr Targeting Tumor Diag & The, Nanning 530021, Guangxi, Peoples R China

来源：

DRUG DISCOVERY TODAY | 2021年 / 26卷 / 08期

基金：

国家高技术研究发展计划(863计划); 美国国家科学基金会;

关键词：

Pharmacogenomics; Next-generation sequencing; Population group; Biomarkers; US FDA; IMPACT; VALIDATION; GUIDELINES; DIVERSITY; GENOMICS; HEALTH;

D O I：

10.1016/j.drudis.2021.04.015

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pharmacogenomics (PGx) has essential roles in identifying optimal drug responders, optimizing dosage regimens and avoiding adverse events. Population-specific therapeutic interventions that tackle the genetic root causes of clinical outcomes are an important precision medicine strategy. In this perspective, we discuss next-generation sequencing genotyping and its significance for population specific PGx applications. We emphasize the potential of NGS for preemptive pharmacogenotyping, which is crucial to population-specific clinical studies and patient care. We also provide examples that use publicly available population-based genomics data for population-specific PGx studies. Last, we discuss the remaining challenges and regulatory efforts towards improvements in this field.

引用

页码：1776 / 1783

页数：8

共 50 条

[41] Next-generation sequencing
Haferlach, T.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 40 - 41
[42] Next-generation sequencing
Jorge S Reis-Filho
Breast Cancer Research, 11
[43] Next-Generation Sequencing
Le Gallo, Matthieu
Lozy, Fred
Bell, Daphne W.
MOLECULAR GENETICS OF ENDOMETRIAL CARCINOMA, 2017, 943 : 119 - 148
[44] Next-generation sequencing
Reis-Filho, Jorge S.
BREAST CANCER RESEARCH, 2009, 11
[45] Next-generation sequencing
Nature Reviews Drug Discovery, 2010, 9 (6) : 495 - 495
[46] Salivary Gland Cancer in the Era of Routine Next-Generation Sequencing
Todorovic, Emilija
Dickson, Brendan C.
Weinreb, Ilan
HEAD & NECK PATHOLOGY, 2020, 14 (02): : 311 - 320
[47] "What if" Challenge of the Rice Biology in the "Next-Generation" Sequencing Era
Antonio, Baltazar A.
Matsumoto, Takashi
PLANT GENOME, 2009, 2 (01): : 3 - 4
[48] Implications of Tumor Clonal Heterogeneity in the Era of Next-Generation Sequencing
Jacoby, Meagan A.
Duncavage, Eric J.
Walter, Matthew J.
TRENDS IN CANCER, 2015, 1 (04): : 231 - 241
[49] Inherited Susceptibility to Pancreatic Cancer in the Era of Next-Generation Sequencing
Humphris, Jeremy
Chang, David K.
Biankin, Andrew V.
GASTROENTEROLOGY, 2015, 148 (03) : 496 - +
[50] From genomics to functional markers in the era of next-generation sequencing
R. K. Salgotra
B. B. Gupta
C. N. Stewart
Biotechnology Letters, 2014, 36 : 417 - 426

← 1 2 3 4 5 →